Roche to Buy InterMune for $8.3B, Adds Lung Drug

Aug. 25 (Bloomberg) -- Roche is strengthening its portfolio of medicines for respiratory ailments with an agreement to buy InterMune for $8.3 billion in cash. Olivia Sterns reports on “In The Loop.” (Source: Bloomberg)

Venture Capital Stays Resilient in Europe Despite Brexit
15:15 - Alex McPherson, head of ventures at Octopus Ventures VC, talks about the venture capital environment in Europe and the potential tech industry impact of Brexit. He speaks with Bloomberg's Jason Kelly at the Super Return Conference in Berlin on "Bloomberg Markets: European Open." (Source: Bloomberg)
  • Full Show: Bloomberg Daybreak: Americas (02/27)
  • Investec's Stopford Sees No Recession to Stop Bull Market
  • Full Show: Bloomberg Daybreak: Australia (02/28)